Case report: a transcatheter aortic valve replacement failure secondary to COVID-19 infection.
Acute heart failure
Aortic valve
Case report
Prosthetic valve thrombosis
Pulmonary oedema
Thrombosis
Valve replacement
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
17
08
2022
revised:
05
10
2022
accepted:
26
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
28
2
2023
Statut:
epublish
Résumé
Valve thrombosis is a well-documented cause of bioprosthetic valve failure. Case reports have been published of prosthetic valve thrombosis secondary to COVID-19 infection. This is the first case report of COVID-19 associated valve thrombosis in a patient with transcatheter aortic valve replacement (TAVR). A 90-year-old female with atrial fibrillation on therapeutic apixaban and status-post TAVR presented with COVID-19 infection and was found to have severe bioprosthetic valvular regurgitation with features suggestive of valve thrombosis. She underwent valve-in-valve TAVR with resolution of valvular dysfunction. This case report contributes to a growing body of evidence describing the occurrence of thrombotic complications in patients with valve replacement and COVID-19 infection. Increased vigilance and continued investigation are warranted to better characterize thrombotic risk and to inform optimal antithrombotic strategies during COVID-19 infection.
Sections du résumé
Background
UNASSIGNED
Valve thrombosis is a well-documented cause of bioprosthetic valve failure. Case reports have been published of prosthetic valve thrombosis secondary to COVID-19 infection. This is the first case report of COVID-19 associated valve thrombosis in a patient with transcatheter aortic valve replacement (TAVR).
Case summary
UNASSIGNED
A 90-year-old female with atrial fibrillation on therapeutic apixaban and status-post TAVR presented with COVID-19 infection and was found to have severe bioprosthetic valvular regurgitation with features suggestive of valve thrombosis. She underwent valve-in-valve TAVR with resolution of valvular dysfunction.
Discussion
UNASSIGNED
This case report contributes to a growing body of evidence describing the occurrence of thrombotic complications in patients with valve replacement and COVID-19 infection. Increased vigilance and continued investigation are warranted to better characterize thrombotic risk and to inform optimal antithrombotic strategies during COVID-19 infection.
Identifiants
pubmed: 36845835
doi: 10.1093/ehjcr/ytad054
pii: ytad054
pmc: PMC9949707
doi:
Types de publication
Case Reports
Langues
eng
Pagination
ytad054Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
Am J Cardiol. 2020 Oct 1;132:106-113
pubmed: 32773221
Circ Cardiovasc Imaging. 2021 May;14(5):e012118
pubmed: 33541095
Crit Care. 2020 May 29;24(1):272
pubmed: 32471449
JACC Cardiovasc Interv. 2017 Apr 10;10(7):686-697
pubmed: 28385406
JACC Cardiovasc Interv. 2017 Apr 10;10(7):698-700
pubmed: 28385407
J Clin Pharm Ther. 2021 Apr;46(2):519-523
pubmed: 33217032
Can J Cardiol. 2021 Jun;37(6):938.e3-938.e6
pubmed: 33485934
J Am Coll Cardiol. 2015 Dec 1;66(21):2285-2294
pubmed: 26610876
Interact J Med Res. 2020 Sep 1;9(3):e22768
pubmed: 32805702
Eur Heart J Case Rep. 2022 Jan 24;6(2):ytac006
pubmed: 35146323